German Biotech MorphoSys Seeks Nasdaq Listing
MorphoSys, a Germany-based biopharmaceutical company, is aiming for a listing on the Nasdaq exchange hoping to secure approximately $150 million. Source: BioSpace
GSK Walks Away From Acquiring Pfizer Consumer Goods Unit
GlaxoSmithKline has decided not to make a play for Pfizer's consumer health business. The decision came one day after another potential suitor walked away from a potential deal. Source: BioSpace
Akebia Announces $85M Public Offering
Akebia Therapeutics, a kidney disease company, announced plans to offer and sell about $85 million of its common stock in an underwritten public offering. Source: BioSpace
Pharma Execs are Attractive Candidates for Healthcare Leadership Roles
Healthcare companies are now looking at pharma executives for leadership roles as the landscape of healthcare is dramatically changing. Source: BioSpace
Endo, Watson, Teikoku to Pay $270 Million to Settle Lidoderm Pay-For-Delay Suits
Endo International and two other drugmakers agreed to pay $270.8 million to settle class-action lawsuits over a pay-for-delay arrangement for a generic of Endo’s Lidoderm lidocaine pain patch. Source: Drug…
House Republicans Send Right-to-Try Bill to the Senate
The House passed its version of federal right-to-try legislation, sending it for re-consideration by the Senate, which passed a similar bill last August. Source: Drug Industry Daily
Omnibus Spending Bill Hikes FDA Funding by $135 Million
The House passed an omnibus spending bill Thursday that boosts FDA funding by $135 million for fiscal 2018 for a total of $2.9 billion in discretionary spending. Source: Drug Industry…
Poor Mid-Stage Results Sink AbbVie’s Plans for Cancer Drug
After disappointing mid-stage results and discussions with the FDA, AbbVie will not ask for accelerated approval for its lung cancer drug. Source: BioSpace
Rheos Medicines Launches with $60 Million
Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease. Source: BioSpace
U.S. House Passes Right-to-Try Legislation on Second Attempt
The second time proved to be the charm for the U.S. House of Representatives to pass right-to-try legislation that would provide terminally ill patients access to experimental drugs without the…
- Go to the previous page
- 1
- …
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- …
- 610
- Go to the next page